Responsive BP reduction within minutes in the postoperative clinical setting1,3

91.8% of patients on CLEVIPREX achieved treatment success*3

The primary endpoint was the incidence of treatment failure, defined as the inability to decrease SBP by ≥15% from baseline or the discontinuation of study treatment for any reason within the 30-minute period after study drug initiation.3

Rotate icon
P<0.0001 Treatment success rate*3 CLEVIPREX (n=61) (n=49) PLACEBO 0 20 40 60 80 100 91.8 20.4 Success rate (%)

*Treatment success was defined as a reduction of SBP of ≥15% from baseline within the 30-minute period from study drug initiation.

Rotate icon
Mean change from baseline in SBP (mmHg) –50 –40 –30 –20 –10 0 0 5 10 15 20 25 30 Time (minutes) Mean change in SBP (mmHg)during 30-minute infusion1 PLACEBO† CLEVIPREX

†The decrease in placebo group SBP reflects the number of placebo patients (N=49 at baseline) who bailed out during the 30-minute infusion period (N=10 remaining at 30 minutes).

Target SBP reduction (≥15% from baseline) achieved with a median time of 5.3 minutes3